Watch our Facebook Live now! Listen as FORCE founder Sue Friedman and Oncotype DX® patient ambassador Punita K. talk about why advocating for yourself while navigating cancer matters and how genomic and genetic tests can help. | Exact Sciences

In celebration of the 20th anniversary of Exact Sciences' Oncotype DX® test, we’re exploring its impact with the first patient who used it. | Katie Couric Media

▶️ The Oncotype DX test analyzes the genes of your breast cancer to predict how aggressive it is and whether chemotherapy would help. It helps your doctor personalize your treatment so you can avoid unnecessary chemo if your cancer is less likely to return. Learn more: https://www.primrmed.com/cancer-education/oncotype-dx-for-breast-cancer #breastcancer #oncotypedx #chemotherapy #personalizedtreatment #breastcancerawareness #bcam #patienteducation #simplecancerexplanations #health #cancer #oncol

The Oncotype DX Breast Recurrence Score® test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. And now, the National Comprehensive Cancer Network® (NCCN®) has updated its guidelines and recognized the Oncotype DX® test as the only assay that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1-3 positive axillary lymph nodes. Read more: https://exas.co/3dU3rEB | Exact